GLP-3R (5 mg/vial)

Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, is surging in 2026 popularity for metabolic research, enabling studies on multi-pathway insulin sensitization, profound fat reduction, and energy expenditure in experimental models—ideal as a flagship for weight loss-focused labs seeking next-gen alternatives to dual agonists. For research use only. Not for human or veterinary use.